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Background/aim: This study aimed to analyze delays in diagnosis and treatment by defining the related demographic and clinical
factors, to reveal obstacles, and to develop essential attempts to help reduce treatment delays.
Materials and methods: We created a questionnaire on the subject of delays in diagnosis and treatment in tuberculosis (TB) control
to be administered to the patients. The forms were distributed to dispensaries across the country by the General Directorate of Public
Health via an official letter.
Results: The study included 853 new patients with smear-positive pulmonary TB. The mean patient delay was 18.06 ± 22.27 days, the
mean diagnosis delay was 35.63 ± 34.86 days, and the mean treatment delay was 0.90 ± 2.39 days. We found no association between sex,
age, literacy, residential location, the presence of chronic respiratory diseases, and patient delay. It was determined that patient delay was
shorter for patients with hemoptysis, fever, dyspnoea, and chest pain. In women, the diagnosis delay was longer than in men.
Conclusion: In the diagnosis process of patients with tuberculosis, it was determined that there was an improvement in the patient
delay; however, the improvement in the diagnosis delay was still not acceptable as an ideal duration.
Key words: Health policy, tuberculosis control, patient delay, diagnosis delay

1. Introduction
Early diagnosis, administering treatment with a standard
regimen, and starting treatment immediately are some
of the primary targets for the elimination of tuberculosis
(TB) [1–3]. Within the context of prevention, the End
TB Strategy suggests a patient-centered care to focus on
early diagnosis, treatment, and prevention [4]. Delays in
the diagnosis and treatment of pulmonary TB are a great
obstacle in the elimination of TB globally [5].
Delays in diagnosis and treatment increase the rate of
contamination [6]. Contamination most probably happens
before the effective treatment of the index cases [7]. With
treatment, the frequency of coughing of the patient with
TB and the number of bacteria in their sputum decreases
rapidly, which indicates both symptomatic relief and
decreased contamination [8,9]. With effective treatment,
the contamination feature of TB is diminished practically
within 2–3 weeks [2].
Delays in diagnosis and treatment lead to increasing
complications and long-term periods of contagiousness in
public, which causes higher amounts of debts and increase

in mortality [10]. The evaluation of delays in diagnosis is
important for interpreting the control activity of TB and
defining the obstacles [11]. Delays between the onset of TB
symptoms and the initiation of the treatment are caused
either by the patient, healthcare system, or a combination
of both. Delays in diagnosis are usually attributed to
healthcare systems [12].
Turkey has passed through a health transformation
[13] and this transformation has had positive effects on
the control of TB [14]. This will be the first study that
almost entirely consists of a Turkish database. We aimed
to analyze delays in diagnosis and treatment by defining
the related demographic and clinical factors, to reveal
obstacles, and to develop essential attempts to help reduce
treatment delays.
2. Methods
2.1 National TB control
The planning and administration of the TB control
program in Turkey are under the responsibility of the TB
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departments affiliated with the General Directorate of
Public Health within the Ministry of Health of the Republic
of Turkey. These departments are currently planning
and carrying out TB control work within tuberculosis
dispensaries with the coordination of the Provincial
Health Directorates, family physicians, hospitals, and all
institutions of health.
In Turkey, as a healthcare service, all diagnostic and
treatment procedures of TB are maintained without
charge. The institutions of the Ministry of Health provide
all the necessary medications without charge for the
patients with TB and the individuals with a history of
contact with TB bacilli, including cases that are multi
drug-resistant, without considering the social insurance
status of the patient.
In Turkey’s TB control program, the endpoint units are
the TB dispensaries. Patients who are diagnosed as having
TB are referred to the dispensaries, which are responsible
for duties including diagnosis, treatment, patient followups, notifying patients, registration, keeping statistics,
immunization, scanning, supplying medication, education,
information activities, coordination, and consultation
services.
2.2. Study design
We planned this study for the notification of patients with
TB based on the delay in diagnosis and treatment and to
determine the obstacles. We created a questionnaire on the
subject of delays in diagnosis and treatment in TB control
to be administered to the patients. The form basically tries
to obtain information about the patients and the delays
in their diagnosis and treatment. The questions included
the general demographic characteristics of the patients,
major symptoms, the date of therapy initiation, the date of
presentation to a healthcare institute, the first admission
to the medical department, the date of presentation when
the TB diagnosis was made, the medical department of
the physician who first diagnosed TB, and the date of
the initiation of the treatment. We received the written
consent of the General Directorate of Public Health in
order to provide and use the data.
2.3. Data collection
The questionnaires were distributed to dispensaries across
the country by the General Directorate of Public Health
via an official letter. The data were collected from 157
dispensaries located in 81 provinces. The questionnaires
were administered by the physicians of the dispensaries
to patients with smear-positive pulmonary TB who
volunteered to complete the questionnaire. The patients
were diagnosed between January 1 and December 31 2018
and were registered to the dispensaries. Before completing
the questionnaire, all the patients provided their written
informed consent. The patients were enlightened regarding
any further questions by the physicians of the dispensaries.
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The smear-negative pulmonary TB cases, extrapulmonary
TB cases, retreatment TB cases, and the patients under 18
years were not included in the study.
2.4. Definitions
Patient delay: The delay between the symptom onset and
the admission of the patient to a healthcare institution
(time unit = days);
Diagnosis delay: The delay between the admission to a
healthcare institution and receiving a diagnosis (time unit
= days);
Treatment delay: The delay between the diagnosis and
the initiation of the treatment (time unit = days);
Total delay: The delay between the symptom onset and
the treatment administration (time unit = days).
2.5. Statistics
Statistical analyses were performed using the SPSS software
version 18 (SPSS Inc., Chicago, IL, USA). The normality
of distribution of the variables was evaluated using visual
(histograms and probability graphics) and analytical
methods (Kolmogorov–Smirnov/Shapiro–Wilk tests). The
time frames of the first examination admission and the
diagnosis were compared within various groups according
to symptoms, the institution, and the diagnosing physician
using the Kruskal–Wallis test because these parameters
were not normally distributed. Comparisons between the
two variables were performed using the Mann-Whitney
U test and evaluated using the Bonferroni correction.
For variables in which at least one was not normally
distributed or ordinal, the correlation coefficient and
statistical significance were calculated using the Spearman
test. In the analysis, a type 1 error rate of 5% was used for
possible statistically significant factors .
3. Results
This nationwide study involved 853 new patients with
smear-positive pulmonary TB. The age range of the
patients was 58.05 ± 17.85 [median = 60 (range 21–
96)] years. Among the participants, 581 (68.1%) were
male, and 31.9% (n = 272) were female. As for the place
of residence, 170 (20%) of the patients were living in
villages. The literacy rate was 85.2% (n = 727) among the
participants and 14.8% (n = 126) were illiterate. Moreover,
158 patients (18.5%) had a history of chronic pulmonary
disease. When it comes to smoking habits, it was seen
that 413 patients (48.4%) were current smokers, 38.3% (n
= 327) were never smokers, and the remaining 13.3% (n
= 113) were former smokers. The most common initial
symptom was cough (n = 509, 59.7%). The physicians who
initially admitted the patients were from the departments
of chest diseases (n = 340, 39.9%), internal medicine (n
= 175, 20.5%), and family physicians (n = 139, 16.3%).
We detected the patient delay as 18.06 ± 22.27 [median
= 10 (range 0–113)] days, the diagnosis delay as 35.63 ±
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34.86 [median = 23 (range 0–151)] days, and the treatment
delay as 0.90 ± 2.39 [median = 0 (range 0–14) days]. The
majority (88.4%, n = 754) of the patients were diagnosed
by a chest diseases physician. Three institution types that
had the highest diagnostic rates were university hospitals
and education and research hospitals (32.8%, n = 280),
chest diseases hospitals (29.3%, n = 250) and government
hospitals (22.0%, n = 187), respectively (Table 1).
There was no significant correlation between age and
the patient delay (r = –0.048, P > 0.05). The patient delay
showed no association (P > 0.05) with sex. Furthermore,
there was no association between literacy levels and the
patient delay (P > 0.05). However, an association was
found between smoking and the patient delay (P < 0.001).
In current smokers, the patient delay (median = 16 days,
n = 413) was longer than in never smokers (median = 11
days, n = 440). No association was found between the
presence of chronic respiratory disease (CRD) and the
patient delay (P > 0.05). Also, patient delay showed no
association according to the residence of the patients (P >
0.05) (Table 2).
According to the initial symptoms of the patients,
the patient delay showed a statistical significance (P <
0.001). Within the multiple comparisons performed
using the Mann–Whitney U test, it was determined that
this difference was caused by patients who had dyspnoea,
fever, hemoptysis, and chest pain. The patient delay of the
patients with hemoptysis (median = 1 day), fever (median
= 4 days), dyspnoea (median = 5 days), and chest pain
(median = 6 days) was significantly shorter compared with
the other symptom types (P < 0.001). On the other hand,
there was no statistical significance between the patients’
first symptoms and the diagnosis delay (P > 0.05) (Figures
1 and 2).
Between the factors of age and the diagnosis delay, a
low degree of correlation was present (r = 0.102, P = 0.003).
The diagnosis delay in women (median = 27 days, n = 272)
was found to be longer than in men (median = 19 days, n
= 581) (P < 0.001). No significance was found between the
diagnosis delay and the CRD status (P > 0.05). In current
smokers (median = 19 days, n = 413), the diagnosis delay
was found to be shorter than in never smokers (median =
26 days, n = 440) (P < 0.001). There was a moderate degree
of correlation between the total number of consulted
physicians and the diagnosis delay (r = 0.460, P = 0.001).
There was a statistically significant correlation between the
total number of examinations and the diagnosis delay (r =
0.515, P = 0.001) (Table 3).
There was a significant difference between the patients’
status of initial admission to a physician and the diagnosis
delay (P < 0.001). According to the Mann–Whitney U
test used for multiple comparisons, it was found that
this difference was caused by the patient group that was

admitted by physicians from dispensaries, chest diseases
departments, and emergency room (ER) wards. The
diagnosis delay was significantly shorter in patients who
were admitted by dispensary physicians (median = 4.5
days), chest diseases specialists (median = 11 days), and ER
ward physicians (median = 16 days) than other specialists
(Table 4).
After admission to healthcare institutions, statistically
significant differences were found between diagnosis
periods (P < 0.001). As a result of multiple comparisons
performed using the Mann–Whitney U test, the diagnosis
period after admission to university training and research
hospitals were found to be significantly longer (median =
6 days) when compared with other institutions (P < 0.001)
(Table 5).
4. Discussion
Our study, which was performed regarding the delays
in the diagnosis and treatment of TB, is the first one to
include major data of Turkey. In our study, the patient
delay was 18.06 ± 22.27 days, the diagnosis delay was 35.63
± 34.86 days, and the treatment delay was 0.90 ± 2.39 days.
We found no associations between the patient delay and
sex, age, literacy, residential location, and the presence of
CRD. However, there was an association between smoking
status and the patient delay. It was determined that the
patient delay was shorter in patients with hemoptysis,
fever, dyspnoea, and chest pain. Also, the patient delay was
longer in women than in men.
In Turkey, studies concerning delays in diagnosis and
treatment are usually based on hospitals or clinics. In a
retrospective study conducted in a university hospital in
Ankara between 1994 and 1997, which was based on the
time period between the symptom onset and treatment in
patients with TB, it was determined that the median days
was 62, based on 28 patients who were smear-positive for
TB [15]. In a study carried out with 81 patients who were
TB smear-positive and hospitalized in 1998 and had started
their treatment in a training and research hospital in Ankara,
which is a reference center for TB, it was determined that
the days of the patient delay was 82.6 ± 70.7, the physician
delay was 41.4 ± 55.8, and the total delay was 124.0 ±
113.7 days [16]. In a study performed in 1999 in the chest
diseases department of a military hospital in Istanbul, it
was determined that the total delay in diagnosis in all the
patients was found to be a mean 16.3 days, (median = 21
days) [17]. According to a study conducted in 1999 with
134 patients hospitalized for smear-positive pulmonary TB
in a training and research hospital in Istanbul, which was
a reference center for TB, the mean days of admission for
the patients were 26.9, the referral was 9.2, the time period
for diagnosis was 3.9, and the initiation of the treatment
was 1.3 days. The median time periods were 17.5, 3.5, and
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Table 1. General characteristics of the study groups.
Sex n, (%)
Residence n, (%)
Education n, (%)
Previous chronic pulmonary disease n, (%)
Smoking status n, (%)

Initial symptom n, (%)

Initial physician on admission n, (%)

Diagnosing physician n, (%)

Institution of diagnosis n, (%)

Time period of delay, mean days ± SD

SD: Standard deviation; ER: Emergency room.
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Male
Female
City center
Town center
Village
Illiterate
Literate
No
Yes
Never
Current
Former
Cough
Fever
Loss of weight
Night sweating
Chest pain
Fatigue
Hemoptysis
Dyspnoea
Hoarseness
Loss of appetite
Chest diseases
Internal medicine
Family physician
ER physician
Otorhinolaryngology
Dispensary’s physician
Infectious diseases
Other
Chest diseases
Dispensary’s physician
Infectious diseases
Internal medicine
Otorhinolaryngology
Primary care physician
Other
University—training and research hospital
Chest diseases hospital
Government hospital
Dispensary
Private hospital
Delay of the patient
Delay in the diagnosis
Delay in the treatment

581 (68.1)
272 (31.9)
333 (39)
350 (41)
170 (20)
126 (14.8)
727 (85.2)
695 (81.5)
158 (18.5)
327 (38.3)
413 (48.4)
113 (13.3)
509 (59.7)
84 (9.8)
75 (8.8)
59 (6.9)
35 (4.1)
36 (4.2)
26 (3.0)
22 (2.6)
4 (0.5)
3 (0.4)
340 (39.9)
175 (20.5)
139 (16.3)
107 (12.5)
36 (4.2)
22 (2.6)
19 (2.2)
15 (1.8)
754 (88.4)
63 (7.4)
16 (1.9)
13 (1.5)
2 (0.2)
2 (0.2)
3 (0.4)
280 (32.8)
250 (29.3)
187 (22.0)
78 (9.1)
58 (6.8)
18.06 ± 22.27
35.63 ± 34.86
0.90 ± 2.39
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Table 2. The analysis of parameters that could affect the time period of admission.
Sex

Female
Mean ± SD

Male
Med (Min-Max) Mean ± SD

Patient delay (days) 23.47 ± 25.38 14 (0–114)
Education

Literate
Mean ± SD

CRD present
Mean ± SD

14 (0–117)

P
0.475m

Nonsmoker
Med (Min-Max)

20.63 ± 23.52

11 (0–120)

Med (Min-Max) Mean ± SD

Centrum
Mean ± SD

25.63 ± 27.06

P
0.001m

CRD absent

Patient delay (days) 23.34 ± 25.36 11.5 (0–114)
Residence

Med (Min-Max)

Med (Min-Max) Mean ± SD

Patient delay (days) 26.31 ± 25.88 16 (0–114)
CRD

P
0.745m

Nonliterate

Current smoker
Mean ± SD

14 (0–120)

Med (Min-Max) Mean ± SD

Patient delay (days) 22.99 ± 24.43 14 (0–120)
Smoking

Med (Min-Max)

23.34 ± 24.60

Med (Min-Max)

23.39 ± 24.74

14 (0–120)

Town center

Village

Med (Min-Max) Avg ± SD

Patient delay (days) 23.59 ± 23.91 (14–120)

P
0.959m

Med (Min-Max) Avg ± SD

24.38 ± 25.77

(14–113)

Med (Min-Max) P
0.094K
20.94 ± 24.65 (10–117)

CRD: Chronic respiratory disease; SD: Standard deviation; Med: Median; Min: Minimum; Max: Maximum .

3.1 days, respectively [18]. In another study carried out in
the same hospital in 2001 with 204 hospitalized patients
with smear-positive pulmonary TB, it was determined that
the mean days of admission were 31.4, the referral was
22.1 days, diagnosis was 3.3 days, and the initiation of the
treatment was 1.4 days. The median time periods were 17.5,
11.0, 1.5, and 1.0 days, respectively [19]. Later, a new study
was carried out in the same hospital in 2010 with 136 new
patients hospitalized with pulmonary TB. In this study, the
mean and median days between the initiation of symptoms
and the initiation of treatment were 64.7 and 48 in smearpositive cases (n = 71) and 99.8 and 61 days in smearnegative cases (n = 65) [20]. In another reference hospital
for TB in Istanbul, a study performed in 2004 revealed that
out of 151 new patients with smear-positive pulmonary
TB, the mean days between the symptom onset and the first
visit to a physician was 46.4, the delay of referral was 28.9
days, the delay of diagnosis was 2.4 days, and the delay of
treatment initiation was 0.8 days [21]. Based on national
parameters, it was determined that in Turkey the patient
delay, the diagnosis delay, and the treatment delay had
decreased. However, the diagnosis delay, which was found
to be 35 days, cannot be accepted as an ideal duration.
Among all disciplines, the knowledge and awareness of
TB diagnosis could be an underestimated issue. Therefore,
patients admitted with pulmonary symptoms are nearly
always evaluated with a suspicion of TB.
In a review study in which studies from 78 countries
were evaluated and systematically compiled, the patient
delay was found as 81 days, the physician delay was

29.5 days, and the treatment delay was 7.9 days [5]. The
diagnosis delay was still an obstacle in TB prevention
and control programs in low- and medium-income levels
[11]. Health illiteracy, poverty, and other personal reasons
cause delays in admission to healthcare institutions, and
consequently, delays in the diagnosis of TB. Inadequate
health systems also cause delays in diagnosis and treatment.
The health system in Turkey has been through a period of
transformation [13] and one of the positive outcomes of
this transformation in TB control is the shorter time delays
in diagnosis and treatment.
The most frequent reason for the patient delay is that
patients with TB tend to neglect the symptoms [22]. In a
previous study performed in Italy, one of the most frequent
reasons for delays in treatment was the light nature of
the symptoms (82%) and feeling healthy (76%) [23]. In
our study, we found that patients whose first symptoms
were cough, weight loss, night sweats, exhaustion, and
hoarseness tended to neglect these symptoms and consult a
physician much later. We found an association between the
first symptoms of patients and the patient delay. However,
we found no association between the first symptoms and
the diagnosis delay.
There were no associations between the patient delay
and sex in our study. We found that the diagnosis delay
was longer in women (median = 27 days) than in men
(median = 19 days). In a study performed in England, the
diagnostic delay was found to be associated with being
female [24]. In China, female sex was related with a risk of
diagnostic delay [25,26].
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Figure 1. The relationship between the initial symptoms and patient delay: According
to the initial symptoms of the patients, the patient delay showed a statistical
significance (P < 0.001). It was determined that this difference was caused by patients
who had dyspnoea, fever, hemoptysis, and chest pain.

Figure 2. The relationship between the initial symptoms and the diagnosis delay:
There was no statistical significance (P > 0.05) between the patients’ first symptoms
and the diagnosis delay.

Unlike most studies, we found no relation between the
patient delay and age, literacy, and the place of residence.
The patient delay was longer in smokers (median = 16
days) than in non-smokers (median = 11 days). Thus, in
current smokers, the diagnosis delay was shorter (median
= 19 days) than in non-smokers (median = 26 days). In
a study conducted in Serbia, a medium, positive, and
statistically significant correlation was found between the
number of cigarette smoked and the patient delay [27].
We determined that there was a medium correlation
between the total number of consultant physicians and the
delay in the diagnosis, but there was a higher correlation
between the number of examinations and the diagnosis
delay. A study performed in India found out that an
increased number of consultations and the diagnostic
delay were statistically correlated [28]. In a report from
Ethiopia, it was emphasized that the systems of initial
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admission to practitioners were independent indicators of
delays in health systems [29]. In a study from Switzerland,
one of the main indicators of delays in the health system
was evaluated by at least 3 or 4 physicians before initiating
the treatment [30].
We found an association between the patients’ first visit
to a physician and the diagnosis delay. We determined that
the diagnosis delay was significantly shorter in patients
who were consulted by chest physicians, dispensary
physicians, and ER ward physicians than by other
physicians. In a study performed in Italy, it was observed
that the delay was longer when patients were first evaluated
by family physicians [23]. According to a study performed
in Ethiopia, seeing a family physician first was one of the
independent indicators of the health system [29].
Efforts should be focused on finding patients using
the existing systems and developing new strategies to

TÜRKKANI et al. / Turk J Med Sci
Table 3. The analysis of the parameters that could affect the time period of diagnosis.
Sex
Diagnosis delay (days)
Smoking
Diagnosis delay (days)
CRD
Diagnosis delay (days)

Female

Male

Mean ± SD

Med (Min-Max)

Mean ± SD

Med (Min-Max)

40.5 ± 39.74

27 (0–195)

32.1 ± 36.79

19 (0–200)

Current Smoker

P
< 0.001m

Non-Smoker

Mean ± SD

Med (Min-Max)

Mean ± SD

Med (Min-Max)

30.73 ± 35.81

19 (0–198)

38.6 ± 39.49

26 (0–200)

CRD present

P
0.001m

CRD absent

Mean ± SD

Med (Min-Max)

Mean ± SD

Med (Min-Max)

35.80 ± 35.99

26 (1–168)

34.52 ± 38.38

21 (0–200)

P
0.205m

CRD: Chronic respiratory disease; SD: Standard deviation; Med: Median; Min: Minimum; Max: Maximum
Table 4. Analysis of the relationship between the first physician and diagnosis delay.
Physician for diagnosis

n

Avg ± SD (days)

Med (days)

(Min-Max) (days)

Dispensary physician

22

10.05 ± 19.11

4.5

0–92

Chest diseases

340

36.10 ± 27.24

11

0–200

ER physician

107

30.41 ± 28.17

16

0–155

Infectious diseases

19

30.63 ± 33.38

22

5–150

Internal medicine

175

42.91 ± 39.26

30

1–195

Primary care physician

139

44.60 ± 37.73

31

2–176

Otorhinolaryngology

36

58.48 ± 49.70

41

1–184

Other

15

50.47 ± 38.56

41

10–157

P

< 0.001*

SD: Standard deviation; ER: Emergency room; Med: Median; Min: Minimum; Max: Maximum.
*Dispensary, chest, and ER physicians were found to have statistically significant differences in terms of diagnosis time when compared
with other physicians (P < 0.001).
Table 5. The comparison of the time period of diagnosis between the institutions that performed accurate diagnosis of TB.
Institution of diagnosis

n

Mean ± SD (days)

Med (days)

(Min-Max) (days)

University–training and research hospital

280

14.46 ± 21.59

6

0–161

Chest diseases hospital

250

9.19 ± 16.30

3

0–117

Government hospital

187

10.79 ± 18.83

4

0–128

Dispensary

78

5.41 ± 10.99

3

0–92

Private hospital

58

9.86 ± 13.01

4.5

0–64

P

< 0.001*

SD: Standard deviation; Med: Median; Min: Minimum; Max: Maximum.
* University–training and research hospitals were found to have statistically significant differences in terms of diagnosis period when
compared with other hospitals (P < 0.00).

improve patient care-seeking behaviors [11]. We think
that strategies regarding the patient delay are vital for the
success of TB control programs. We care about raising the
awareness of TB, both in the public and among physicians.
We conducted the first study to analyze the delays in

diagnosis and treatment around Turkey and determined
that the Turkish healthcare system has improved its status
in these regards. We advise improving the processes
in order to improve the awareness of patients about the
symptoms of TB and to increase health literacy.
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The limitation of our study can be considered as the
volunteer-based completion of the questionnaires by the
participants. Thus, this situation does not cover all the
patients who were smear-positive in 2018.
In this study covering new patients with smear-positive
TB, no significant relation was found between the patient
delay and age, sex, education, residential location, and the
presence of CRD. However, the patient delay was longer in
current smokers than in never smokers. Also, the patient
delay was less in patients with symptoms of hemoptysis,
fever, and dyspnoea, and chest pain. The diagnosis delay
was significantly shorter in patients who were admitted by
dispensary physicians, chest diseases specialists, and ER
ward physicians than by other specialists. The diagnosis
delay was longer in women than in men. In the diagnostic
process of patients with TB, it was determined that there
was an improvement in the patient delay; however,

the diagnosis delay was still not acceptable as an ideal
duration.
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